Granules India Limited

3.52%

from Operations (Rs. Mn.) Gross margin and margin% (Rs. Mn.) EBITDA and EBITDA margins(Rs. Mn.) 3.52% 8,581 8,883 4,970 57.9% 4,517 50.9% 2,564 29.9% 1,512 17.0% Q2 FY21 Q2 FY22 Q2 FY21 Q

57.9%

Gross margin and margin% (Rs. Mn.) EBITDA and EBITDA margins(Rs. Mn.) 3.52% 8,581 8,883 4,970 57.9% 4,517 50.9% 2,564 29.9% 1,512 17.0% Q2 FY21 Q2 FY22 Q2 FY21 Q2 FY22 Q2 FY21 Q2 FY22 PA

50.9%

nd margin% (Rs. Mn.) EBITDA and EBITDA margins(Rs. Mn.) 3.52% 8,581 8,883 4,970 57.9% 4,517 50.9% 2,564 29.9% 1,512 17.0% Q2 FY21 Q2 FY22 Q2 FY21 Q2 FY22 Q2 FY21 Q2 FY22 PAT (Rs. Mn.) -

29.9%

. Mn.) EBITDA and EBITDA margins(Rs. Mn.) 3.52% 8,581 8,883 4,970 57.9% 4,517 50.9% 2,564 29.9% 1,512 17.0% Q2 FY21 Q2 FY22 Q2 FY21 Q2 FY22 Q2 FY21 Q2 FY22 PAT (Rs. Mn.) -50.67% 1,636

17.0%

and EBITDA margins(Rs. Mn.) 3.52% 8,581 8,883 4,970 57.9% 4,517 50.9% 2,564 29.9% 1,512 17.0% Q2 FY21 Q2 FY22 Q2 FY21 Q2 FY22 Q2 FY21 Q2 FY22 PAT (Rs. Mn.) -50.67% 1,636 EPS (In Rs.)

50.67%

2,564 29.9% 1,512 17.0% Q2 FY21 Q2 FY22 Q2 FY21 Q2 FY22 Q2 FY21 Q2 FY22 PAT (Rs. Mn.) -50.67% 1,636 EPS (In Rs.) -3.34 6.60 807 3.26 Q2 FY21 Q2 FY22 Q2 FY21 Q2 FY22 • • • Income g

18%

ents (In ₹ Mn) Growth momentum witnessed in North America Finished Dosage and PFI segments grew 18% and 10% x i M l a c i h p a r g o e G x i M e u n e v e R % 0 0 . 5 5 8,581 % 0 2 . 7 5

10%

In ₹ Mn) Growth momentum witnessed in North America Finished Dosage and PFI segments grew 18% and 10% x i M l a c i h p a r g o e G x i M e u n e v e R % 0 0 . 5 5 8,581 % 0 2 . 7 5 8,883

8,581 %

PFI segments grew 18% and 10% x i M l a c i h p a r g o e G x i M e u n e v e R % 0 0 . 5 5 8,581 % 0 2 . 7 5 8,883 % 0 9 . 7 1 % 0 8 . 3 1 % 0 7 . 7 % 0 6 . 5 % 0 4 . 0 2 % 0 0 .

8,883 %

and 10% x i M l a c i h p a r g o e G x i M e u n e v e R % 0 0 . 5 5 8,581 % 0 2 . 7 5 8,883 % 0 9 . 7 1 % 0 8 . 3 1 % 0 7 . 7 % 0 6 . 5 % 0 4 . 0 2 % 0 0 . 1 1 % 0 1 . 7 %

1 %

a c i h p a r g o e G x i M e u n e v e R % 0 0 . 5 5 8,581 % 0 2 . 7 5 8,883 % 0 9 . 7 1 % 0 8 . 3 1 % 0 7 . 7 % 0 6 . 5 % 0 4 . 0 2 % 0 0 . 1 1 % 0 1 . 7 % 0 3 . 4 Q2 F

7 %

e u n e v e R % 0 0 . 5 5 8,581 % 0 2 . 7 5 8,883 % 0 9 . 7 1 % 0 8 . 3 1 % 0 7 . 7 % 0 6 . 5 % 0 4 . 0 2 % 0 0 . 1 1 % 0 1 . 7 % 0 3 . 4 Q2 FY21 Q2 FY22 North America

“We expect to pass on some of the increases to our customers from Q3FY22 onwards Pharmaceutical Formulation Intermediates (PFI) segment grew 10% YoY, Finished Dosage (FD) grew 18% YoY and, Active Pharmaceutical Ingredients (API) segment down by 25% YoY mainly due to Paracetamol KSM supply disruption.”

“Due to high volatility and uncertainty in the entire pharmaceutical market segment, we believe that we will not be able to meet our guidance, and it will not be prudent on our part to give any future guidance until the situation become stable.”

As Encl

1

Total GPI products include

1

Corporate address

1

As Encl

Granules India Limited Q2 & H1FY22 Earnings Presentation Safe Harbor The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any investor should subscribe / purchase the company shares. The Company makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information contained herein. This presentation may include certain “forward looking statements”. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements. Important factors that could cause actual results to differ materially f

Total GPI products include

CII – 7 PFOS – 4 Liquid Orals - 3 IMS value for these products is approximately $ 9,614 mn Source IMS MAT Aug 2021 8 Improving returns; increased working capital requirement: 5-year trajectory focus on OCF generation for funding capex while meeting Net Debt & Net debt-to-EBITDA (x) Cash-to-Cash cycle (days) Free Cash Flow (FCF) (In ₹ Mn) 8,704 3.1 9,082 2.4 6,138 2.1 6,058 5,752 1.2 0.7 135 125 114 109 117 2,919 1,615 -172 -1,284 Mar-17 Mar-18 Mar-19 Mar-20 Mar-21 Mar-17 Mar-18 Mar-19 Mar-20 Mar-21 -4,471 Mar-17 Mar-18 Mar-19 Mar-20 Mar-21 ROCE (%) ROE (%) Operating Cash Flow (OCF) 30.7% 27.4% 4,762 4,325 23.7% 14.7% 17.0% 20.5% 21.0% 19.9% 16.7% 12.0% 1,882 2,622 Mar-17 Mar-18 Mar-19 Mar-20 Mar-21 Mar-17 Mar-18 Mar-19 Mar-20 Mar-21 Mar-17 -651 Mar-18 Mar-19 Mar-20 Mar-21 ROCE = [EBIT/Avg. Capital Employed (Total assets-current liabilities]; FCF= CF from operating activities - Capex 9 5-year trajectory: Creating value for stakeholders Revenue - 5-year CAGR 19% Gross Profit & Gross Marg

Corporate address

Floor 2 Block 3 My Home Hub Madhapur Hyderabad 500081 CIN: L24110TG1991PLC012471 Voice: +91 40 69043600 Fax: +91 40 69043602 www.granulesindia.com 532482 GRANULES GRAN:IN GRAN:NS